The Charcot-Marie-Tooth Disease Market Is Growing with the Increasing Prevalence of Charcot-Marie-Tooth Disease

Global Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028

The global charcot-marie-tooth disease market is estimated to be valued at US$ 3459.1 Million in 2027 and is expected to exhibit a CAGR of 23.4% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Charcot-Marie-Tooth (CMT) disease is the most common inherited neurologic disorder that cause nerve damage. CMT is not life threatening and most people with the condition have the same life expectancy as a person without the condition. CMT is a progressive condition, which means the symptoms gradually get worse over time. The degree of disability varies according to the CMT subtype. There's no cure for CMT, but braces, physical/occupational therapy, and other orthopedic devices, and even orthopedic surgery can help cope with the symptoms of the disease. Charcot-marie-tooth disease generally progresses slowly, and it doesn't affect expected life span. CMT cannot be stopped or reversed, but it can reach a point where the progression steadies itself. Available therapies help reduce the symptoms of CMT.

Request Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4698

Competitive Landscape:

Major players operating in the global charcot-marie-tooth disease market are Neurogene Inc., Helixmith Co., Ltd., Bristol-Myers-Squibb Company, MedDay Pharmaceuticals, Acceleron Pharma, Genzyme Corp, Affectis Pharmaceuticals AG, Addex Therapeutics Ltd., Inflectis Bio Science Health Company, Pharnext SA, and Lead Discovery Center GmbH, among others.

Key Market Drivers:

Increasing prevalence of charcot-marie-tooth disease across the globe is expected to augment the growth of the charcot-marie-tooth disease market during the forecast period. For instance, according to MedlinePlus, an online information service produced by the U.S. National Library of Medicine, CMT is the most common genetic disease; 1 in every 3,300 people in the world is affected by charcot-marie-tooth disease.

Moreover, increasing development of novel therapeutics for the treatment of CMT is expected to boost growth of the charcot-marie-tooth disease market. For instance, in October 2020, the CMT Research Foundation launched a new research program to develop a precision medicine approach for charcot-marie-tooth (CMT) disease.

COVID-19 Impact Analysis:

Outbreak of COVID-19 (pandemic) has affected various industries worldwide, and the charcot-marie-tooth disease market is also no exception. The global pandemic has severely impacted the development, production, and supply of pharmaceutical products, as well as development of drugs used to treat CMT. This is attributed to safety measures imposed across the world to curb the spread of the novel coronavirus. This in turn is expected to hinder market growth.

Key Takeaways:

• The charcot-marie-tooth disease market is expected to exhibit a CAGR of 23.4 % during the forecast period due to increased focus towards targeted therapies and increasing research and development activities. For instance, in October 09, 2018, Vitaccess and Pharnext SA launched an international study on charcot-marie-tooth disease. The objective of the study is to better understand the impact of the disease on patients’ daily lives: the burden of CMT, its natural history and treatment, and medical, social, and pharmacoeconomic effects.

• Among regions, North America is expected to witness robust growth in the charcot-marie-tooth disease market owing to the high prevalence of CMT, introduction of novel therapies for the treatment of CMT, and continuous research and development (R&D) in this region. For instance, according to MedlinePlus, CMT is the most common inherited disorder that affects an estimated 150,000 people in the United States.

Moreover, in February 2019, Pharnext announced that the Food and Drug Administration (FDA) granted Fast Track designation for the development of PXT3003 for the treatment of patients with Charcot-Marie-Tooth disease Type 1A (CMT1A).

Buy Now this Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4698

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837